19 completed. 19 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 19 |
| Phase 2 | 5 | Completed 5 |
Follow Dutasteride: new trials by email Literature Review of Dutasteride trials Research Report on Dutasteride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia DKF-313, Dutasteride, Tadalafil - Benign Prostatic Hyperplasia | Phase 3 | Completed | Dongkook Pharmaceutical Co., Ltd. | 667 | 2021-07-27 | 2023-09-21 |
| EAT-DUTA AndroCoV Trial Dutasteride 0.5 mg, Azithromycin, Nitazoxanide - Covid19 | Phase 2 / Phase 3 | Completed | Corpometria Institute | 138 | 2020-06-30 | 2021-01-28 |
| Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy Dutasteride Capsules, Placebo Capsules - Alcohol Use Disorder | Phase 2 / Phase 3 | Completed | UConn Health | 180 | 2019-10-15 | 2025-05-09 |
| Role of Dutasteride in Treatment of Chronic Prostatitis Dutasteride 0.5 mg, Placebo - Dutasteride, Category IIIB Chronic Prostatitis | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2019-01-01 | 2021-02-16 |
| Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Dutasteride, Placebo - Alopecia | Phase 3 | Completed | Stiefel, a GSK Company | 117 | 2014-07-02 | 2018-10-11 |
| Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia Dutasteride 0.5mg capsules, Dutasteride placebo capsules, Tamsulosin 0.2mg tablets - Prostatic Hyperplasia | Phase 3 | Completed | GlaxoSmithKline | 607 | 2014-02-10 | 2019-04-05 |
| A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Dutasteride 0.5 mg - Alopecia | Phase 3 | Completed | GlaxoSmithKline | 120 | 2013-04-14 | 2018-06-20 |
| Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride - Androgenetic Alopecia | Phase 3 | Completed | GlaxoSmithKline | 917 | 2010-10-28 | 2018-08-10 |
| PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA) - Healthy | Phase 2 / Phase 3 | Completed | University of Washington | 32 | 2009-01-01 | 2013-11-15 |
| Effects of Testosterone Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolism in Transmen dutasteride 5 mg/day, Testosterone Undecanoate - Transgenderism, Hypogonadism | Phase 3 | Completed | Unita Complessa di Ostetricia e Ginecologia | 16 | 2008-11-04 | 2020-09-11 |
| Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH) Dutasteride 0.5mg capsule, Dutasteride matched placebo - Benign Prostatic Hyperplasia, Prostatic Hyperplasia | Phase 3 | Completed | GlaxoSmithKline | 253 | 2007-10-01 | 2012-03-21 |
| Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia dutasteride, prostate biopsy - Prostate Cancer | Phase 3 | Completed | Kaunas University of Medicine | 200 | 2007-04-01 | 2018-03-06 |
| Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer Dutasteride - Prostate Cancer | Phase 2 / Phase 3 | Completed | Canadian Urology Research Consortium | 100 | 2007-03-01 | 2016-10-14 |
| A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Dutasteride 0.5mg oral tablets - Alopecia | Phase 3 | Completed | GlaxoSmithKline | 153 | 2006-12-15 | 2018-08-16 |
| Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer dutasteride, placebo - Prostate Cancer | Phase 3 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 450 | 2006-11-01 | 2014-01-10 |
| Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects Dutasteride, Placebo - Prostatic Hyperplasia | Phase 3 | Completed | GlaxoSmithKline | 378 | 2006-02-17 | 2018-09-26 |
| Testosterone and Its Metabolites in GID testosterone undecanoate alone, testosterone undecanoate plus letrozole, testosterone undecanoate plus dutasteride - Transsexualism | Phase 3 | Completed | Unita Complessa di Ostetricia e Ginecologia | 15 | 2005-05-01 | 2018-03-21 |
| Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years - Prostatic Hyperplasia | Phase 3 | Completed | GlaxoSmithKline | 4844 | 2003-11-01 | 2017-02-28 |
| "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Dutasteride, Placebo - Neoplasms, Prostate | Phase 3 | Completed | GlaxoSmithKline | 8231 | 2003-03-01 | 2016-09-23 |
Prostatic Hyperplasia (5) · Alopecia (4) · Prostatic Neoplasms (4) · Transsexualism (2) · Alcoholism (1) · COVID-19 (1) · Hypogonadism (1)
GlaxoSmithKline (8) · Unita Complessa di Ostetricia e Ginecologia (2) · Ain Shams University (1) · Canadian Urology Research Consortium (1) · Corpometria Institute (1) · Dongkook Pharmaceutical Co., Ltd. (1) · Kaunas University of Medicine (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Stiefel, a GSK Company (1) · UConn Health (1) · University of Washington (1)
Japan (5) · United States (5) · South Korea (4) · Taiwan (4) · Argentina (3) · Brazil (3) · Canada (3) · Chile (3) · Italy (3) · Lithuania (3) · Mexico (3) · Russia (3) · Belgium (2) · Bulgaria (2) · China (2)
Andy Goren, MD (1) · Carlos G. Wambier, MD, Ph.D. (1) · Choung-Soo Kim, M.D.,Ph.D (1) · Cristina M Meriggiola, MD (1) · Daimantas Milonas, assist professor (1) · Ethan J. Halpern, MD (1) · Flavio A. Cadegiani, MD, MSc, Ph.D. (1) · Jonathan Covault, MD, PhD (1) · Larry S Goldeng (1) · Laurence Klotz, MD (1) · Stephanie T Page, MD, PhD (1)
PMID 22017520, PMID 22998915, PMID 23541458, PMID 23587564, PMID 26165588, PMID 26184556, PMID 26893187, PMID 27378134, PMID 28396999, PMID 30214036, PMID 32856605, PMID 36570649
P50AA027055 (1)